IL-4Rα–STAT6 signaling amplifies IL-1Ra production in ABCB5+ dermal mesenchymal stem cell–macrophage crosstalk
Biochemical and Biophysical Research Communications · 2026-09 · 830 · 154259
DOI: 10.1016/j.bbrc.2026.154259 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2026-09. Verfasst von Karmveer Singh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergic Diseases, Ulm University, N27, Albert-Einstein-Allee 23, Ulm, 89081, Germany. Hauptthemen laut MEDLINE: STAT6 Transcription Factor, Mesenchymal Stem Cells, Macrophages, Interleukin 1 Receptor Antagonist Protein. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boston Children's Hospital.
Abstract (Originalsprache)
ABCB5+ dermal mesenchymal stem cells (DMSCs) regulate macrophage activation via interleukin-1 receptor antagonist (IL-1Ra), but upstream control mechanisms remain unclear. Here, we define a dual-signal model integrating inflammatory and type 2 cytokine pathways. IFNγ/LPS priming initiates IL-1Ra expression, while IL-4 signaling through IL-4Rα amplifies this response via STAT6 in both ABCB5+ DMSCs and macrophages. In coculture, ABCB5+ DMSCs drive macrophage polarization toward a CD206+/CD163+ phenotype with enrichment of CD163-expressing subsets. IL-4Rα blockade with dupilumab inhibits STAT6 activation, suppresses IL-1Ra amplification, and attenuates expansion of this IL-4Rα-dependent macrophage population. Collectively, these findings identify IL-4/IL-4Rα/STAT6 signaling as a conserved amplifier of IL-1Ra-mediated stromal-immune crosstalk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Allergic Diseases, Ulm University, N27, Albert-Einstein-Allee 23, Ulm, 89081, Germany.
- Transplant Research Program, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA, 02115, USA.
- Transplant Research Program, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA, 02115, USA; Renal Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA.
- Division of Genetics, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA; Department of Medicine, VA Boston Healthcare System, 1400 VFW Parkway, West Roxbury, MA, 02132, USA.
- Department of Dermatology and Allergic Diseases, Ulm University, N27, Albert-Einstein-Allee 23, Ulm, 89081, Germany. Electronic address: Karin.Scharffetter-Kochanek@uniklinik-ulm.de.
- Transplant Research Program, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA, 02115, USA; Renal Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA; Department of Dermatology, B…
Förderung
- Boston Children's Hospital
Zitieren
APA
Singh, K., Wilson, B. J., Waaga-Gasser, A. M., Schatz, S., Hainzl, A., Yeung, P. C., Maity, P., Frank, N. Y., Scharffetter-Kochanek, K., & Frank, M. H. (2026). IL-4Rα–STAT6 signaling amplifies IL-1Ra production in ABCB5+ dermal mesenchymal stem cell–macrophage crosstalk. Biochemical and Biophysical Research Communications, 830, 154259. https://doi.org/10.1016/j.bbrc.2026.154259
Vancouver
Singh K, Wilson BJ, Waaga-Gasser AM, Schatz S, Hainzl A, Yeung PC, et al. IL-4Rα–STAT6 signaling amplifies IL-1Ra production in ABCB5+ dermal mesenchymal stem cell–macrophage crosstalk. Biochemical and Biophysical Research Communications. 2026;830:154259. doi:10.1016/j.bbrc.2026.154259
BibTeX
@article{Singh2026,
author = {Singh, Karmveer and Wilson, Brian J and Waaga-Gasser, Ana Maria and Schatz, Susanne and Hainzl, Adelheid and Yeung, Philip C and Maity, Pallab and Frank, Natasha Y and Scharffetter-Kochanek, Karin and Frank, Markus H},
title = {IL-4Rα–STAT6 signaling amplifies IL-1Ra production in ABCB5+ dermal mesenchymal stem cell–macrophage crosstalk},
journal = {Biochemical and Biophysical Research Communications},
year = {2026},
volume = {830},
pages = {154259},
doi = {10.1016/j.bbrc.2026.154259}
}
EUVIMED